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Background: The development of diagnostic tools to assess restenosis risk after stent deployment may 
enable the intervention to be tailored to the individual patient, for example by targeting drug-eluting 
stent’s use to high risk patients, with the goal of improving safety and reducing costs. The CCNB1 
gene (encoding cyclin B1) positively regulates cell proliferation, a key component of in-stent 
restenosis (ISR). We therefore hypothesized that single nucleotide polymorphisms (SNPs) in CCNB1 
may serve as useful tools in risk stratification for ISR.  
 
Methods and Results: We identified 3 SNPs in CCNB1 associated with increased restenosis risk in a 
cohort of 284 patients undergoing coronary angioplasty and stent placement (rs350099: TT vs. 
CC+TC, OR=1.82, 95%CI=1.09-3.03, p=0.023; rs350104: CC vs. CT+TT, OR=1.82, 95%CI=1.02-
3.26, p=0.040; rs164390: GG vs. GT+TT, OR=2.27, 95%CI=1.33-3.85, p=0.002). These findings were 
replicated in another cohort study of 715 patients (rs350099: TT vs. CC+TC, OR=1.88, 95%CI=0.92-
3.81, p=0.080; rs350104: CC vs. CT+TT, OR=2.23, 95%CI=1.18-4.25, p=0.016; rs164390: GG vs. 
GT+TT, OR=1.87, 95%CI=1.03-3.47, p=0.040). Moreover, the haplotype containing all three risk 
alleles is associated with higher CCNB1 mRNA expression in circulating lymphocytes and increased 
ISR risk (OR=1.43, 95%CI=1.00-1.823, p=0.039).The risk variants of rs350099, rs350104 and 
rs164390 are associated with increased reporter gene expression through binding of transcription 
factors NF-Y, AP-1 and SP1, respectively.  
 
Conclusions: Allele-dependent transcriptional regulation of CCNB1 associated with rs350099, 
rs350104 and rs164390 affects the risk of ISR. These findings reveal these common genetic variations 
as attractive diagnostic tools in risk stratification for restenosis.  
 





The use of stents has increased the safety of percutaneous coronary interventions (PCI) and decreased 
restenosis rates compared with conventional balloon angioplasty.1 Preclinical studies demonstrate a 
pivotal role of cell cycle regulatory genes in vascular smooth muscle cell (VSMC) proliferation and 
neointimal lesion development induced by mechanical injury,2 and restenosis incidence has been 
reduced to 5-10% by the use of drug-eluting stents (DES) that locally deliver cytostatic drugs that limit 
VSMC hyperplasia, compared with 20-30% in patients revascularized with bare metal stents (BMS).1, 
3, 4 However, probably as a consequence of delayed target vessel reendothelialization due to reduced 
endothelial cell proliferation, DES deployment increases the occurrence of late stent thrombosis, which 
is associated with a high mortality rate.1 Patients fitted with DES are therefore submitted to longer 
duration dual antiplatelet therapy than patients receiving BMS. In addition to these clinical limitations, 
DES are costlier than BMS. The development of diagnostic tools to assess restenosis risk may enable 
the intervention to be tailored to the individual patient, for example by targeting DES use to patients at 
higher risk, with the goal of improving safety and reducing costs. 
The incidence of restenosis is highly influenced by clinical, biological, procedural and lesion-
related risk factors.4 However, information on restenosis biomarkers is scarce. Single nucleotide 
polymorphisms (SNPs) are recognized as suitable markers of disease predisposition.5 SNPs in the 
human genome occur on average once every 300 nucleotides (~10 million SNPs), making them the 
most common type of genetic variation. SNPs reported to influence restenosis risk affect platelet 
activation, leukocyte recruitment, the inflammatory response, metalloproteinases, lipid metabolism, 
oxidative stress, nitric oxide, the renin-angiotensin system and cell proliferation (reviewed in).4, 6, 7 
Interestingly, the 838C>A SNP in CDKN1B (encoding the tumor suppressor p27Kip1) has been 
associated with restenosis risk after coronary stenting, which might be due to augmented VSMC 
proliferation caused by reduced CDKN1B promoter activity in patients carrying the risk allele.8 
However, other SNPs in CDKN1B or in TP53 (encoding the tumor suppressor p53) showed lack of 
association with restenosis risk.8, 9 In the present study, we investigated a potential association of 
restenosis risk with SNPs in the CCNB1 gene (encoding cyclin B1). CCNB1 is essential for cell 
proliferation and its ablation in the mouse is embryonically lethal.10 Several regulatory mechanisms are 
necessary to ensure that cyclin B1 protein accumulates appreciably only during the G2/M cell cycle 
transition, and deregulated CCNB1 transcription leading to aberrantly high levels of cyclin B1 
throughout the cell cycle is associated with excessive hyperplasia in several human cancers.11 Several 
lines of evidence indicate that CCNB1 is also important in the context of cardiovascular disease: its 
expression has been reported in human restenotic tissue obtained by directional coronary 
atherectomy,12 it is induced in balloon-injured rat carotid artery,13, 14 and its inhibition reduces 
neointimal thickening in this animal model.15 Herein, we present evidence from two independent 
cohorts of patients undergoing coronary stent deployment (Clinica Mediterranea and GEnetic risk 
factors for In-Stent Hyperplasia study Amsterdam: GEISHA)8 cohorts showing that alleles of the SNPs 
rs350099, rs350104 and rs164390, located in regulatory regions of CCNB1, are associated with higher 
CCNB1 mRNA expression and increased risk of in-stent restenosis (ISR) after PCI. We furthermore 









Patients. The Clinica Mediterranea cohort included 434 patients scheduled for PCI in Clinica 
Mediterranea (Naples, Italy) who were recruited between January- December 2004. Inclusion criteria 
were elective PCI with planned cobalt-chromium stent, and de novo lesion in a native coronary artery. 
Of the initial cohort, 101 patients were excluded because of implantation of at least 1 DES (n=77) or 
inadequate blood sample storage (n=24), leaving a final total of 333 enrolled patients. Of these, 284 
(85%) underwent a routine coronary angiographic follow-up 6-9 months after PCI and were included 
in this study. The cobalt-chromium stents implanted were MultiLink Vision (Abbott Vascular, Abbott 
Park, Illinois) and Driver (Medtronic CardioVascular, Santa Rosa, California). All patients were 
treated with 100 mg aspirin and 75 mg clopidrogel daily for at least 1 month after PCI. The local ethics 
committee approved the study protocol, and all patients gave written informed consent. Peripheral 
blood samples were taken from all patients before PCI. Samples were collected into trisodium-citrate 
tubes and immediately placed on ice. Within 1 hour of collection, blood samples were centrifuged 
(4000 rpm, 20 minutes) and plasma harvested and stored at -80°C until analysis. Plasma total 
cholesterol, HDL-cholesterol, LDL-cholesterol and triglycerides were measured by enzymatic 
techniques. Estimated glomerular filtration rate (eGFR) was calculated by applying the modification of 
diet in renal disease formula. Chronic kidney disease was defined as an eGFR<50 ml/min/1.73m2. 
Clinical characteristics of patients are summarized in Supplemental Table-S1. Patients received 
intracoronary isosorbide dinitrate (0.1-0.3-mg) prior to initial and final angiograms to achieve maximal 
vasodilatation. Angiographic measurements were performed with an automated computer-based 
system (Cardiovascular Angiographic Analysis Syste; Pie Medical Imaging; Maastricht, The 
Netherlands). Follow-up restenosis was analyzed by measurement of minimal lumen diameter by 
independent observers blinded to the genotype data. The following variables were also assessed: acute 
gain, defined as the difference between the minimal lumen diameter before and after the procedure; 
late loss, defined as the minimal lumen diameter after the procedure minus the minimal lumen 
diameter at follow-up; and loss index, defined as the average ratio of late loss to acute gain. Binary 
angiopraphic ISR was defined as >50% narrowing of the lumen diameter in the target segment 
(defined as all portions of the vessel that received treatment within the stent zone, including the 
proximal and distal 5-mm margins). Angiographic characteristics and major adverse coronary events 
(MACE) are summarized in Supplemental Table-S2 and -S3, respectively.  
The clinical and angiographic characteristics of the GEISHA patients who were successfully 
treated for stable angina via BMS placement in a native coronary artery have been described 
previously.8  All patients were treated with 100 mg aspirin and 250 mg ticlopidine BID or 75 mg 
clopidrogel daily for one month after PCI and 100 mg aspirin thereafter. Quantitative coronary 
angiography was performed between 6 and 12 months after BMS placement as described,16 and 
clinical follow-up at 1 year was obtained. The primary endpoints were angiographic binary ISR (>50% 
diameter stenosis) and late lumen loss in minimal luminal diameter at follow-up. The secondary 
endpoints were coronary artery bypass grafting (CABG), target lesion revascularization (TLR, defined 
as repeat revascularization of the stented segment or within 5 mm margins proximal or distal to the 
stent by either repeat PCI or CABG), repeat PCI, non-fatal myocardial infarction, death, or the 
combined endpoint of MACE.  
 
Genotyping of SNPs. Blood samples from patients of Clinica Mediterranea cohort were analyzed by 
SNPlex according to the manufacturer’s recommendations (Applied Biosystems, Carlsbad, California, 
US). Polymorphisms were genotyped in the healthy sample by high resolution melting curves using a 
480 LightCycler System and LightCycler 480 High Resolution Melting Master Kit (Roche, Basel, 
Switzerland). Supplemental Table-S4 shows the sequence of the primers used to PCR amplify the 
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genomic regions containing each SNP. The genotype for each curve was identified by direct 
sequencing of 10 samples with similar curves using a 3730 sequencing analyzer under standard 
conditions (Applied Biosystems). In the GEISHA cohort, SNPs were genotyped using the Taqman 
assay (Applied Biosystems). Reactions were performed using the LC480 (Roche Diagnostics).  
 
Statistical analysis. Results are expressed as means±SEM for in vitro experiments and as mean±SD 
for the cohort studies. Differences in continuous values in restenotic versus non-restenotic subjects (as 
defined by the angiographic lesion progression) were performed by the Student’s t test or the Mann-
Whitney U test, as appropriate. Categorical variables were analyzed by 2 test. In both cohorts, 
analysis for possible deviations of the genotype distribution from that expected for a population in 
Hardy-Weinberg equilibrium was performed by 2 test. Logistic regression analysis was performed to 
determine the association between the genotypes and ISR or TLR (repeated PCI or CABG). For 
genetic association, we first tested the codominant model and then used dominant or recessive models 
if two genotypes showed a similar effect. The association between the genotypes and TLR was also 
assessed by Cox proportional regression analysis. Follow-up ended for each individual at the time of 
the first occurrence of TLR. Patients without TLR were censored at 1 year after stent placement and 1 
patient who died during follow-up was censored at the date of death. The proportional hazards 
assumption was examined by plotting the log(-log(survival)) versus the log of survival time. Event-
free survival curves were calculated by Kaplan-Meier analysis, and differences between groups were 
calculated with the log-rank statistic. Haplotypes in the Clinica Mediterranea cohort were inferred with 
SNAPStats using the Expectation Maximization algorithm and Odds Ratio was calcutaled by logistic 
regression.17  For the GEISHA study, from the obtained unphased SNP genotype data, haplotype 
frequencies and their effect on risk of TLR were estimated using weighted Cox regression as 
described.18 Based on the inferred haplotypes, patients were grouped as those having one or no copies 
of the risk haplotype (TCG) and as those having two copies of the risk haplotype. Differences were 
considered statistically significant at p<0.05, as determined by paired 2-sided Student’s t test 
(experiments with two groups) or one-way or two-way ANOVA followed by Bonferroni’s or 
Dunnett’s test (experiments with more than two groups). Statistical analyses were performed with 









SNPs rs350099, rs350104 and rs164390 in CCNB1 are associated with ISR risk. To investigate 
whether polymorphic variants in CCNB1 are associated with risk of ISR, we selected SNPs located in 
the transcriptional regulatory region (promoter and 5’-untranslated region) that have a minor allele 
frequency greater than 0.2. The 5 SNPs that fulfilled these criteria (Fig.1A) were genotyped in a cohort 
of 284 patients from Clinica Mediterranea who underwent coronary revascularization with BMS and 
angiographic follow-up (see Methods and Supplemental Tables-S1,-S2,-S3).  Of these patients, 116 
developed ISR. Genotyping was successful in >95% of samples for SNPs rs350099 (-957[T/C]), 
rs350104 (-475[T/C]), and rs164390 (+102[G/T]), and in 86% of samples for rs352626 (-710[C/T]) 
and rs8192258 (1055[-/A]). Genotype distribution of the non-restenotic control group was in Hardy-
Weinberg equilibrium (p>0.05). Statistical analysis revealed a significant association between -
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957[T/C], -475[T/C] and +102[G/T] allele distribution and the incidence of angiographic (binary) 
restenosis, which was significant in crude analysis (not shown) and after adjustment for variables 
including age, gender, hypertension, diabetes mellitus, type of angina, statin therapy and family history 
of coronary artery disease (CAD) (Table 1). Moreover, the false positive report probability test19 was 
0.17 for a prior probability of 0.25, which supports a genuine association of SNPs -957[T/C], -
475[T/C] and +102[G/T] with ISR risk in this cohort.  
We next analyzed the GEISHA population for the three SNPs that exhibited significant 
association in our pilot study (-957[T/C], -475[T/C], +102[G/T]). As in Clinica Mediterranea 
population, BMS were used in the GEISHA cohort. Clinical and angiographic characteristics have 
previously been described in detail.8 Of a total of 715 patients, DNA was obtained from 688, and TLR 
occurred in 55 patients. Failure of genotyping for -957[T/C], -475[T/C] and +102[G/T] was 9%, 1.9% 
and 1.5%, respectively. All genotype distributions were in Hardy-Weinberg equilibrium (p>0.05). 
Consistent with the results in the Clinica Mediterranea cohort, we found in GEISHA a statistically 
significant association between -475[T/C] and +102[G/T] and clinical ISR (based on TLR occurrence) 
after adjusting for age, gender, hypertension, smoking, diabetes mellitus, statin therapy and family 
history of CAD (Table 2). We also observed increased risk in -957TT compared with -957(TC+CC) 
patients (Odds Ratio=1.88), which almost reached statistical significance (p=0.080, Table 2). 
Moreover, Kaplan-Meyer analysis revealed reduced cumulative TLR-free survival in carriers of the 
ISR risk genotypes of each SNP, with differences reaching statistical significance for +102[G/T] (Log-
rank p=0.040) or very close to significance (-957[T/C]: Log-rank p-value=0.057; -475[T/C]: Log-rank 
p=0.056) (Figure 2). To explore the strength of the observed associations, we assessed whether these 
associations persisted after Cox proportional regression analysis including age, gender, hypertension, 
smoking, diabetes, statin therapy and family history of CAD. Our results demonstrate increased risk of 
clinical ISR in -957TT (Hazard Ratio [HR], 1.95; CI, 0.99-3.83; p=0.053), -475CC (HR, 2.38; CI, 
1.01-5.61; p=0.048) and +102GG (HR, 2.04; CI, 1.04-4.01; p=0.040) patients when considering the 
interval of time between stent deployment and TLR (Table 3). 
  
The haplotype containing all three restenosis-risk allelic variants is associated with augmented 
risk of ISR and CCNB1 mRNA expression. Having demonstrated that the -957T, -475C and +102G 
alleles are associated with higher ISR risk, we analyzed the CCNB1 haplotype containing these three 
polymorphic variants. In Clinica Mediterranea cohort, four haplotypes were identified with frequencies 
above 1% in both the restenotic and non-restenotic groups (Haplotypes 1-4, Supplemental Table-S5). 
Analysis by the D, D’ and R2 methods revealed that -957[T/C], -475[C/T] and +102[G/T] are in 
linkage disequilibrium (Supplemental Table-S6). Haplotype 1, containing the restenosis risk alleles 
of all three SNPs (T/C/G), was the most frequent (48.8%) in the Clinica Mediterranea population 
(Supplemental Table-S5) and exhibited statistically significant association with increased ISR risk 
when compared to all other haplotypes (OR=1.43, 95%CI=1.00-1.823, p=0.039) (Fig.3A). The 
analysis of this association was very similar after adjustment for multiple variables, including age, 
gender, hypertension, diabetes mellitus, statin therapy, type of angina and family history of CAD 
(OR=1.41, 95%CI=0.99-2.00, p=0.055).  
We also performed haplotype analysis in the GEISHA cohort where haplotype 1 was also the 
most frequent (47.6%, Supplemental Table-S7). We found statistically significant association with 
increased TLR when comparing haplotype 1 versus all other haplotypes (HR=2.87; CI=1.17-7.04; 
p=0.02, Cox regression analysis with data corrected for age, hypertension, smoking, diabetes mellitus, 
statin therapy and family history of CAD). In addition, Kaplan-Meyer estimates of TLR-free survival 
also showed decreased survival in haplotype 1 compared with all other haplotypes with a p-value very 
close to significance (p=0.058) (Fig. 3B).  
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Taken together, these studies suggest a significant association between haplotype containing all 
three restenosis-risk allelic variants and increased risk of ISR. We next sought to investigate possible 
associations between CCNB1 expression and haplotypes 1 and 2, the most frequent haplotypes in our 
cohorts (see Supplemental Table-S5, Table-S7). Analysis of peripheral blood lymphocytes isolated 
from healthy volunteers revealed a 2.23-fold increase in CCNB1 mRNA expression in haplotype 1 
versus haplotype 2 carriers (p=0.0044, Fig.3C; see subjects characteristics in Supplemental Table-
S8). 
 
The restenosis-risk T allelic variant of -957[T/C] generates a binding site for Nuclear Factor-Y 
(NF-Y). Since -957[T/C], -475[T/C] and +102[G/T] are located in potential regulatory regions in the 
CCNB1 gene and are associated with mRNA expression level in circulating lymphocytes, we assessed 
whether the restenosis-risk allelic variants of these SNPs cause increased CCNB1 expression through 
differential transcription factor binding. Previous studies revealed that the CCNB1 promoter contains 
two CCAAT boxes at positions -17/-13 and +16/+20 that are essential for gene transcription through 
binding of NF-Y.20 Our in silico analysis predicted that the restenosis-risk T allelic variant of -
957[T/C], but not the C allele, generates an additional CCAAT motif in the CCNB1 promoter 
(Fig.1B). We evaluated the functionality of this putative CCAAT box by electrophoretic mobility shift 
assays (EMSAs) using nuclear extracts of HeLa cells and radiolabeled probes (Supplemental Table-
S9). Incubation with the NF-Y(-25/-7) probe, containing the canonical CCAAT box at position -17/-13 
in the CCNB1 promoter, generated a retarded band (Fig.4A, lane 2) that was efficiently competed out 
by an excess of either unlabeled NF-Y(-25/-7) sequence (lanes 3,4) or an oligonucleotide spanning the 
-957T sequence (lanes 5,6). This retarded band was not competed out by an equivalent molar excess of 
the unlabeled -957C sequence (lanes 7,8) or the mutated NF-Y(-25/-7) sequence (NF-Y mutant, lanes 
9,10). We also generated radiolabeled -957T and -957C probes to assess DNA-binding activity directly 
associated to these sequences. Consistent with the results of the competition studies, the -957T probe 
generated a retarded band with the same electrophoretic mobility as that produced by NF-Y(-25/-7), 
which was specifically supershifted with anti-NF-YB antibody (Fig.4B, lanes 1-8), and was not 
observed in binding reactions with -957C probe (Fig.4B, lanes 9-12). Thus, the restenosis-risk -957T 
allele of rs350099, but not the -957C variant, generates a NF-Y binding site in the human CCNB1 
promoter.  
 
The restenosis-risk C allelic variant of -475[T/C] generates a binding site for activator protein 1 
(AP-1) with higher affinity than the T allele. Our in silico analyses predicted that the C allelic 
variant of -475[C/T], but not the T allele, generates an AP-1 binding site (Fig.1B). Incubation of 
nuclear extracts from U2OS cells with probes for -475C (Fig.5A, lanes 6,14) or -475T (lanes 10,19) 
generated a major retarded band of the same electrophoretic mobility as that obtained with AP-1 
consensus probe (lane 2). This band was efficiently competed out with an excess of unlabeled -475C, -
475T or AP-1 consensus oligonucleotides (lanes 3, 7, 11, 15, 16, 17, 20, 21, 22), but not with 
unrelated NF-Y consensus (lanes 4,8,12). We noted that the -475C probe produced a more intense 
retarded nucleoprotein complex than the -475T probe (Fig.5A, lanes 6,14 vs. 10,19). Consistent with 
this finding, unlabeled -475C oligonucleotide was more efficient than -475T oligonucleotide at 
competing out DNA-binding activity associated with AP-1 consensus probe (Fig.5B).  
We next carried out supershift experiments using antibodies specific for the canonical AP-1 
family members c-Fos and c-Jun. Anti-c-Fos (Fig.5C, upper autoradiograph) and anti-c-Jun (Fig. 
5C, lower autoradiograph) both produced a supershift when tested against AP-1 consensus, -475C or 
-475T probes (lanes 3,6,9,12,15,17), but not against a probe containing the consensus binding site for 
specificity protein 1 (SP1) (data not shown). Consistent with the results of Fig.5A, the anti-c-Fos and 
anti-c-Jun supershifted bands were more intense with -475C than with -475T probe (Fig.5C, lane 6 vs. 
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9, and 15 vs. 17). Thus, the ISR-risk -475C allele of rs350104 in the human CCNB1 promoter binds 
AP-1 factors with higher affinity than -475T. 
 
The restenosis-risk G allelic variant of +102G[G/T] in CCNB1 generates a binding site for SP1. 
The G allele of +102[G/T] generates a GC-rich sequence very similar to the consensus SP1 binding 
site.21 Incubation of U2OS nuclear extracts with an SP1 consensus probe generated a retarded band 
(Fig.6A, lanes 2,9) that was efficiently competed by excess unlabeled oligonucleotides corresponding 
to SP1 consensus (lanes 3,10) or to +102G (lanes 4-7), but not to +102T (lanes 11-14). Moreover, a 
+102G probe (Fig.6B, lane 7), but not the +102T probe (lane 12), generated a retarded band with the 
same electrophoretic mobility as that obtained with the SP1 consensus probe (lane 2). The retarded 
band obtained with SP1 and +102G probes was supershifted with anti-SP1 antibody (Fig.6B, lanes 
4,9) but not with isotype-matched anti-MEF2C antibody (Fig.6B, lanes 5,10). Thus, the ISR-risk 
+102G allele of rs164390, but not the +102T allele, generates an SP1 binding site in the human 
CCNB1 promoter. 
 
The -957T, -475C and +102G restenosis-risk alleles increase reporter gene transcription. We next 
tested whether the three restenosis-risk alleles supported enhanced transcription by their corresponding 
putative transcription factors (NF-Y for -957T, AP-1 for -475C and SP1 for +102G). We transiently 
transfected U2OS cells with pGL3-luciferase reporters driven by three tandem repeats of each of the 
polymorphic variants of -957[T/C], -475[C/T] and +102[G/T] (supplemental Table-S10). The 3x(-
957T)-luciferase construct increased reporter gene activity two-fold compared with control pGL3-
luciferase (dashed line), whereas 3x(-957C)-luciferase had no effect (Fig.7A, white bars). 
Importantly, the promoter activity of 3x(-957T)-luciferase was significantly reduced by co-expression 
of a dominant-negative NF-YA mutant (NF-YAdn), while 3x(-957C)-luciferase activity was 
unaffected (Fig.7A, black bars). We also found that c-Fos overexpression, by transfection with 
pEGFP-c-Fos, significantly augmented promoter activity associated with 3x(-475C) compared with 
both pGL3 and 3x(-475T) (Fig.7B). Moreover, additional luciferase activity was achieved with 
3x(+102G), but not with 3x(+102T) when SP1 was overexpressed (Fig.7C). These results suggest that 
the NF-Y, AP-1 and SP1 DNA-binding sites generated in the restenosis-risk -957T, -475C and +102G 







In this study, we show that the SNPs rs350099 (-957[T/C]), rs350104 (-475[C/T]) and rs164390 
(+102[G/T]) located in the 5’-regulatory region of the human CCNB1 gene are associated with risk of 
developing restenosis after coronary stent deployment in two independent cohorts and provide 
molecular insight into these genotype-disease associations. We restricted our analysis to patients who 
received a BMS, in order to avoid potential effects of antiproliferative drugs used in DES that can 
significantly reduce cell-cycle gene expression,13, 22 and may explain negative results observed in other 
genetic association studies focused on cell-cycle regulators.9, 23 We find increased ISR risk in patients 
carrying haplotype 1 (-957T/-475C/+102G), which contains all three restenosis-risk alleles. 
Interestingly, circulating lymphocytes from individuals carrying haplotype 1 have higher CCNB1 
mRNA levels than those carrying haplotype 2 (-957C/-475T/+102T). Consistent with the notion that 
disease susceptibility in humans is influenced by common SNPs that affect gene transcription through 
allelic-dependent transcription factor recruitment,24 we find that the restenosis-risk alleles of -
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957[T/C], -475[C/T] and +102[G/T] generate functional binding sites for NF-Y, AP-1 and SP1, 
respectively, as revealed by DNA-binding and luciferase reporter assays. Increased recruitment of 
these transcription factors to the CCNB1 promoter in individuals with haplotype 1 might therefore 
augment ISR risk by increasing expression of CCNB1, a key positive regulator of cell proliferation and 
neointimal thickening10, 15 (Fig.8).  
Individual patient restenosis risk is to date based on a reduced number of clinical, biological, 
lesion-related and procedural factors,  and efforts to identify high-risk patients based on these variables 
have been only partially successful until now.4 Recently, a predictive model utilizing these common 
variables has been developed to identify patients that will benefit from reduced target vessel 
revascularization by DES deployment.25 However, early prediction accuracy of these models may still 
be improved by using additional individual specific biomarkers such as genetic traits. By using a gene 
candidate approach, we have identified three polymorphisms in the CCNB1 associated to increased 
angiographic restenosis risk in the Clinica Mediterranea cohort of patients who underwent PCI with 
BMS implantation. Importantly, our studies in the larger GEISHA cohort revealed a statistically 
significant association with increased clinical ISR (defined as TLR) for SNPs -475[C/T] and 
+102[G/T], which was close to significance for SNP -957[T/C] (p=0.080) and remained significant 
after Cox proportional regression analysis. Individual candidate gene studies have limitations,7 
however our validation in two independent cohorts and functional studies support the reliability of the 
identified associations. Studies in larger cohorts and prospective studies are nevertheless necessary to 
assess whether diagnostic kits based on genotyping these SNPs in CCNB1 can improve the safety and 
cost-effectiveness of stent use. These studies should also evaluate whether prediction can be improved 
on the basis of combining CCNB1 SNPs and clinical, biological, lesion-related and procedural factors.  
Our functional studies identify likely molecular mechanisms that might underlie the ISR risk 
associated with -957[T/C], -475[C/T] and +102[G/T]. NF-Y (also called CCAAT-binding factor: CBF) 
is a ubiquitous heterotrimeric transcription factor formed from NF-YA, B and C subunits that is 
required for cell proliferation.26-31 We recently found that NF-Y is induced during atherosclerosis and 
restenosis in rodent models and humans, and promotes PDGF-BB-dependent CCNB1 expression, 
VSMC proliferation and neointimal lesion development in a mouse femoral artery denudation model.14 
The results in the current study demonstrate that the restenosis-risk T allele of -957[T/C], but not the C 
allele, generates a CCAAT box at position -959/-955 relative to the CCNB1 transcription initiation site 
which supports specific binding of NF-Y and drives NF-YA-dependent transcription of luciferase 
reporter plasmids. It is interesting to note that proper transcriptional regulation of several cell cycle-
regulated genes requires multiple promoter CCAAT motifs,32 possibly by stabilizing DNA-NF-Y 
complexes33 and increasing the DNA-binding affinity of neighboring co-activators34 (and references 
therein). It is therefore possible that the CCAAT motif at -959/-955 in -957TT homozygotes identified 
in the present work might cooperate with the -17/-13 and +16/+20 proximal CCAAT boxes to boost 
NF-Y-dependent CCNB1 transcription. 
Heterodimeric transcription factors of the AP-1 family control cell differentiation, apoptosis 
and proliferation in response to multiple physiological and pathological stimuli.35 AP-1 is induced after 
balloon angioplasty36-38 and stenting,39 and gene therapy against AP-1 reduces neointima development 
in animal models.36, 40, 41 Our data show that the restenosis-risk C allele of -475[T/C] in the CCNB1 
promoter binds AP-1 with higher affinity that the T variant, and that overexpression of the AP-1 
family member c-Fos significantly augments luciferase activity driven by a tandem repeat of -475C, 
while having no significant effect on a similar construct driven by -475T. Thus, the presence of the -
475C sequence in the CCNB1 promoter may enhance gene transcription through increased recruitment 
of AP-1 transcription factors. 
SP1 is an ubiquitous transcription factor that promotes cell growth by enhancing the expression 
of pro-proliferative genes whose promoters contain the consensus GC-rich sequence.21 We found that 
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the presence of the high-risk ISR +102G allele, but not the +102T variant, generates a sequence that 
binds SP1 and confers SP1-dependent transcriptional activation in reporter assays. Bearing in mind 
previous studies reporting that two or more SP1 binding sites can cooperate in gene transactivation,21 
we speculate that enhanced CCNB1 expression in +102GG homozygous individuals may result from 
the cooperation between the SP1 binding site generated by +102G and the two SP1 target sequences 
present at -259/-255 and -140/-136, which have been shown to be required for efficient CCNB1 
transcriptional activation.21 
In summary, our findings suggest that allele-dependent transcriptional regulation of CCNB1 
associated with the SNPs rs350099, rs350104 and rs164390 affects ISR risk through differential 
recruitment of NF-Y, AP-1 and SP1 (Fig.8). Interestingly, Bouatia-Naji et al. 42 recently reported that 
the A allele of rs13431652 in the G6PC2 promoter generates a functional NF-Y-binding CCAAT box, 
and is strongly associated with elevated fasting plasma glucose in humans. Moreover, a mutation in the 
CCAAT box of the TERC promoter that abrogates NF-Y binding has been associated with human 
telomere disease, thus providing further evidence that allele-specific differences in the recruitment of 
NF-Y can contribute to human disorders.43 Likewise, common functional polymorphisms within the 
promoter of genes associated with lupus or CAD in diabetic patients influence AP-1 DNA-binding 
activity and gene expression.44, 45 Allele-specific SP1 activity may also explain the association between 
several SNPs and susceptibility to mild fasting hyperglycemia, atherothrombotic stroke, and lung, 
breast and ovarian cancer.44, 46-49 Regulation of human gene promoters by polymorphic NF-Y, AP-1 or 
SP1 sites thus appears to contribute to genetically-determined inter-individual variability in diverse 
pathophysiological scenarios. Remarkably, van Tiel and colleagues found that the -838C>A SNP in 
the CDKN1B gene (encoding the tumor suppressor p27Kip1) modulates promoter activity and is 
associated with restenosis risk after coronary BMS implantation.8 Validation in larger cohorts and 
prospective studies comparing head-to-head BMS and DES is necessary to assess whether genotyping 
of common SNPs in cell-cycle regulatory genes may assist physicians in targeting DES use to patients 
at the highest ISR risk in order to improve the safety and cost-effectiveness of stent use. Based on the 
recent results of a systematic testing of literature reported genetic variation associated with coronary 
restenosis,7 these studies should examine a possible joined effect of multiple genetic markers for 






The use of drug-eluting stents (DES) that inhibit vascular smooth muscle cell (VSMC) 
proliferation significantly reduces in-stent restenosis (ISR). DES also inhibit endothelial cell 
proliferation, and ISR inhibition with these devices therefore comes at the price of delayed or 
incomplete reendothelialization, requiring longer-term antiplatelet therapy to prevent late in-stent 
thrombosis. The development of diagnostic tools to assess ISR risk may enable the intervention 
to be tailored to the individual patient, for example by targeting DES’ use to high risk patients. In 
the present study, we investigated a potential association of ISR risk with single nucleotide 
polymorphisms (SNPs) in the CCNB1 gene encoding cyclin B1, a positive cell cycle regulator 
which is expressed in human restenotic tissue and is essential for neointimal thickening in the rat 
carotid artery model of balloon angioplasty. By analyzing two independent cohorts, we show that 
the SNPs rs350099, rs350104 and rs164390 located in the 5’-regulatory region of the CCNB1 
gene are associated with higher CCNB1 mRNA expression and elevated ISR risk after coronary 
stent deployment. Our molecular studies indicate that these SNPs affect CCNB1 expression and 
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ISR risk through differential recruitment of the transcription factors NF-Y, AP-1 and SP1. 
Validation in larger cohorts and prospective studies comparing head-to-head DES and bare metal 
stents is necessary to assess whether genotyping rs350099, rs350104 and rs164390 may assist 
physicians in targeting DES use to patients at the highest ISR risk in order to improve the safety 
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Table 1. Statistical analysis of ISR risk associated with SNPs in the human CCNB1 gene: 
Clinica Mediterranea cohort 
 
 















CC+CT 141 49 (34.7%) 
-475[C/T] 
(rs350104) 





CT+TT 188 73 (38.8%) 
+102[G/T] 
(rs164390) 






GT+TT 164 58 (35.4%) 
 
 
The Odds ratios were estimated using a logistic model adjusted for age, gender, hypertension, 
diabetes mellitus, type of angina, statin therapy at time of stenting and family history of CAD. 
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Table 2. Statistical analysis of ISR risk associated with SNPs in the human CCNB1 gene: 
GEISHA cohort 
 
SNP Genotype Total TLR p-value Odds Ratio 95% CI 
-957[C/T] 
(rs350099) 
TT 146 17 (11.64%) 
0.080 
1.88 (TT vs 
CC+TC) 
0.92-3.81 
CC+CT 479 32 (6.68%) 
-475[C/T] 
(rs350104) 
CC 89 13 (14.61%) 
0.016 
2.23 (CC vs 
TT+TC) 
1.18-4.25 
CT+TT 586 41 (6.99%) 
+102[G/T] 
(rs164390) 
GG 159 19 (11.95%) 
0.040 
1.87 (GG vs 
TT+GT) 
1.03-3.47 
GT+TT 519 34 (6.55%) 
 
 
The Odds ratios were estimated using a logistic model adjusted for age, gender, hypertension, 
smoking, diabetes mellitus, statin therapy at time of stenting and family history of CAD 
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Hazard ratio estimated using a Cox proportional hazard model adjusted for age gender, hypertension, 
smoking, diabetes, statin therapy at time of stenting and family history of CAD  
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Figure Legends  
 
Fig.1. Analysis of SNPs in the CCNB1 gene. (A) Summary of SNPs that were included in the 
genotyping analysis. Position is defined as SNP location relative to transcription initiation site (+1). 
MAF: minor allele frequency. (B) -957T and -957C are the T or C polymorphic variants of rs350099, 
respectively. The -957T variant generates a consensus NF-Y binding site (CCAAT box).  -475C and -
475T are the C and T polymorphic variants of rs350104, respectively. The -475C variant generates a 
consensus AP-1 binding site (TGAG box). +102G and +102T are the G and T polymorphic variants of 
rs164390, respectively. The +102G variant generates a consensus SP1 binding site (GGGGCGGGGC 
box). 
 
Fig.2. Kaplan-Meier estimates of clinical ISR-free survival in the GEISHA cohort. (A)  Kaplan-
Meier curves of TLR-free survival in patients carrying -957TT genotype vs the combined -957TC+-
957CC genotypes. Log-rank p=0.057. (B)  Kaplan-Meier curves of TLR-free survival in patients carrying 
-475CC genotype vs the combined -475TC+-475CC genotypes. Log-rank p=0.056. (C)  Kaplan-Meier 
curves of TLR-free survival in patients carrying +102GG genotype vs the combined -957GT+-957GG 
genotypes. Log-rank p=0.040. The number at risk at 0, 2, 4, 6, 8, 10 and 12 months after PCI are shown 
for each SNP. 
 
 
Fig.3 Human peripheral lymphocytes from donors carrying the high-risk H1 CCNB1 haplotype 
(T/C/G) express increased levels of CCNB1 mRNA. (A) Statistical analysis of restenosis risk in CCNB1 
haplotypes: H1 (high risk alleles of all three SNPs) vs all other haplotypes (analysis of Clinica 
Mediterranea cohort). (B)  Kaplan-Meier curves of TLR-free survival in patients carrying H1 (T/C/G) 
haplotype vs all other haplotypes (analysis of GEISHA cohort). The p-value is from log-rank test. The 
number at risk at 0, 2, 4, 6, 8, 10 and 12 months after PCI are shown. (C) Relative CCNB1 mRNA levels 
in peripheral blood lymphocytes isolated from 31 healthy human donors carrying either H1 haplotype (-
957T/-475C/+102G (T/C/G)) or the H2 haplotype (-957C/-475T/+102G (C/T/T)). Results were analyzed 
by unpaired, 2-sided Student’s t test. 
 
Fig.4. The -957T restenosis-risk allelic variant of -957[C/T] in CCNB1 generates a binding site 
for NF-Y. EMSAs using HeLa cell nuclear extracts and the indicated probes/competitors (see 
Supplementary Table-S8). Autoradiographs are representative of 3-5 experiments. (A) Competition 
assays using molar excesses of the indicated unlabeled oligonucleotides. The graph shows mean 
relative intensities of the retarded probe:NF-Y complex (n=3  assays). Black bar: control without 
competitor (=1). Results were analyzed by one-way ANOVA followed by Dunnet’s multiple 
comparison test. *: p<0.01 and **: p<0.001 versus control without competitor. (B) Supershift assay 
using the indicated antibodies. No Ab: control without antibody. 
 
Fig.5. The -475C restenosis-risk allelic variant of -475[C/T] in CCNB1 generates a sequence with 
higher affinity than the -475T variant for binding AP-1. EMSAs using U2OS cell nuclear extracts 
and the indicated probes/competitors (see Supplementary Table-S8). Autoradiographs are 
representative of n=3-5 experiments. (A, B) Competition assays using molar excesses of the indicated 
unlabeled oligonucleotides. The graph shows mean relative band intensities of the retarded probe:AP-1 
complexes (n=5 assays). Black bar: control without competitor (=1). Results were analyzed by one-
way ANOVA followed by Bonferronni’s multiple comparison test. *: p<0.01 and **: p<0.001 versus 
control without competitor. (C) Supershift assays using the indicated antibodies. Only retarded bands 
are shown.  
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Fig.6. The +102G restenosis-risk allelic variant of +102[G/T] in CCNB1 generates a binding site 
for SP1. EMSAs using U2OS cell nuclear extracts and the indicated probes/competitors (see 
Supplementary Table-S8). Autoradiographs are representative of n=3-5 experiments. (A) Competition 
assays using molar excesses of the indicated unlabeled oligonucleotides. The autoradiograph shows the 
retarded probe:SP1 complexes and the graph shows mean relative band intensities of retarded 
probe:SP1 complexes (n=4-7 assays). Black bar: control without competitor (=1). Results were 
analyzed by one-way ANOVA followed by Dunnett´s multiple comparison test. *: p<0.001 versus 




Fig.7. The -975T, -475C and +102G restenosis-risk allelic variants increase reporter gene 
expression via NF-Y, c-Fos and SP1. U2OS cells were co-transfected with pRL-Renilla (control for 
transfection efficiency) and the indicated reporter vectors (depicted above the graphs). Results are 
represented as the firefly luciferase/renilla luciferase ratio relative to control pGL3-luciferase (=1). 
Results were analyzed by one-way ANOVA followed by multiple comparison test. (A) Assays were 
performed without (white bars) or with (black bars) co-transfected expression vector encoding the NF-
YAdn dominant-negative mutant (n=12 replicates from 4 independent experiments). Results are 
expressed relative to control pGL3-luciferase (=1, dashed line). *: p<0.001 versus pGL3-luciferase and 
3x(-957C)-luciferase; #:  p<0.01 versus control 3x(-957T)- luciferase. (B) Assays were performed with 
co-transfected expression vector encoding c-Fos (n=10 replicates from 5 independent experiments). 
Results are expressed relative to pGL3-luciferase (=1). **: p<0.01 versus pGL3-luciferase; #: p<0.01 
versus 3x(-475T)- luciferase. (C) Assays were performed with co-transfected expression vector 
encoding SP1 (n=15 replicates from 5 independent experiments). Results are expressed relative to 
pGL3-luciferase (=1). *** : p<0.001 versus pGL3-luciferase; # : p<0.05 versus 3x(+102T)- luciferase.   
 
 
Fig.8. Model of increased risk of ISR through polymorphic transcriptional factor-dependent 
regulation of CCNB1 gene transcription. The -957T polymorphic variant of rs350099, the -475C 
variant of rs350104 and the +102G variant of rs164390 increase recruitment of the transcription factors 
NF-Y, AP-1 and SP1, respectively, to the human CCNB1 gene promoter. Increased recruitment of NF-
Y, AP-1 and SP1 in subjects bearing the H1 haplotype (-957T/-475C/+102G) may lead to higher 
CCNB1 mRNA expression and VSMC proliferation, thus contributing to a higher risk of ISR. In 
contrast, reduced recruitment of these transcription factors in subjects bearing the H2 haplotype (-






















rs8192258 (-1055[-/A]) -1055               -/A 0.284
rs350099 (-957[T/C]) -957                T/C 0.320
rs352626 (-710[T/C]) -710                T/C 0.478
rs350104 (-475[T/C]) -475                T/C 0.285
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Months after PCI: 0      2      4      6      8     10    12
CT+CC: 457  439  422  408  386  362  171
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8 p = 0.0044
Number at risk
Months after PCI:   0      2      4      6      8     10    12
All other haplotypes: 457  434  419  402  378  348  168
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